Black Diamond Therapeutics (BDTX) Short Interest Ratio & Short Volume → My system predicted the BA collapse – now it’s issuing an AI warning (From Chaikin Analytics) (Ad) Free BDTX Stock Alerts $5.74 -0.20 (-3.37%) (As of 05/14/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Black Diamond Therapeutics Short Interest DataCurrent Short Volume2,000,000 sharesPrevious Short Volume1,760,000 sharesChange Vs. Previous Month+13.64%Dollar Volume Sold Short$11.14 millionShort Interest Ratio / Days to Cover3.0Last Record DateApril 30, 2024Outstanding Shares56,250,000 sharesPercentage of Shares Shorted3.56%Today's Trading Volume412,607 sharesAverage Trading Volume616,444 sharesToday's Volume Vs. Average67% Short Selling Black Diamond Therapeutics ? Sign up to receive the latest short interest report for Black Diamond Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatBDTX Short Interest Over TimeBDTX Days to Cover Over TimeBDTX Percentage of Float Shorted Over Time Ad Paradigm PressBiden to Drop BOMBSHELL June 13th?Biden’s days are numbered! According to a former CIA and Pentagon insider… He’s about to drop out of the presidential race on June 13th!Click here now to see his shocking evidence. Black Diamond Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/20242,000,000 shares $11.14 million +13.6%N/A3 $5.57 4/15/20241,760,000 shares $9.19 million -13.7%N/A2.8 $5.22 3/31/20242,040,000 shares $10.34 million +12.7%N/A3.4 $5.07 3/15/20241,810,000 shares $8.67 million +1.7%N/A3.1 $4.79 2/29/20241,780,000 shares $9.16 million -5.3%N/A3.1 $5.15 2/15/20241,880,000 shares $9.51 million -21.7%N/A3.5 $5.06 Get the Latest News and Ratings for BDTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Black Diamond Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/31/20242,400,000 shares $9.22 million -33.0%N/A4.5 $3.84 1/15/20243,580,000 shares $10.67 million -1.1%N/A7.9 $2.98 12/31/20233,620,000 shares $10.17 million -0.6%N/A7.1 $2.81 12/15/20233,640,000 shares $9.86 million +6.4%N/A7 $2.71 11/30/20233,420,000 shares $8.00 million +1.8%N/A6.2 $2.34 11/15/20233,360,000 shares $7.56 million +0.3%N/A6 $2.25 10/31/20233,350,000 shares $6.30 million +12.8%9.8%6.2 $1.88 10/15/20232,970,000 shares $6.80 million +24.3%8.7%5.6 $2.29 9/30/20232,390,000 shares $6.86 million +68.3%7.0%3.9 $2.87 9/15/20231,420,000 shares $5.04 million +24.6%4.1%0.3 $3.55 8/31/20231,140,000 shares $3.84 million +7.6%3.2%0.3 $3.37 8/15/20231,060,000 shares $3.36 million +1.9%2.9%0.3 $3.17 7/31/20231,040,000 shares $3.88 million -67.3%4.7%0.3 $3.73 7/15/20233,180,000 shares $15.42 million -38.4%14.4%0.8 $4.85 6/30/20235,160,000 shares $26.06 million +166.0%23.4%1.3 $5.05 6/15/20231,940,000 shares $4.07 million No Change8.4%31.3 $2.10 5/31/20231,940,000 shares $3.61 million No Change8.4%22.7 $1.86 5/15/20231,940,000 shares $3.74 million -1.5%8.4%24.1 $1.93 4/30/20231,970,000 shares $2.82 million No Change8.6%24.1 $1.43 4/15/20231,970,000 shares $2.94 million -1.5%8.6%22.6 $1.49 3/31/20232,000,000 shares $3.78 million -1.5%8.7%17.3 $1.89 3/15/20232,030,000 shares $3.41 million +3.1%8.8%13.5 $1.68 2/28/20231,970,000 shares $3.49 million -1.0%8.6%14.6 $1.77 2/15/20231,990,000 shares $5.23 million No Change8.7%14.6 $2.63 1/31/20231,990,000 shares $5.97 million -2.0%8.7%13.3 $3.00 1/15/20232,030,000 shares $5.36 million -2.4%8.9%9.6 $2.64 12/30/20222,080,000 shares $3.74 million +5.6%9.1%10 $1.80 12/15/20221,970,000 shares $2.96 million No Change8.6%10.5 $1.50 11/30/20221,970,000 shares $4.16 million -2.5%8.6%11.1 $2.11 11/15/20222,020,000 shares $4.79 million -2.4%8.8%11.2 $2.37 10/31/20222,070,000 shares $4.78 million -7.2%9.1%11.3 $2.31 10/15/20222,230,000 shares $2.83 million +6.2%9.8%14.9 $1.27 9/30/20222,100,000 shares $3.55 million No Change9.2%15.8 $1.69 9/15/20222,100,000 shares $5.50 million -3.7%9.2%11.1 $2.62HUGE BUY ALERT: Move Fast, Musk... (Ad)I recently traveled to Phoenix, Arizona...And based on what I saw out there, I'm prepared to put my reputation on the line. Since 2018, my investment recommendations have averaged 115% per year. But one investment I've just discovered could blow them all away.You won't believe what I saw in Phoenix. BDTX Short Interest - Frequently Asked Questions What is Black Diamond Therapeutics' current short interest? Short interest is the volume of Black Diamond Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 30th, investors have sold 2,000,000 shares of BDTX short. Learn More on Black Diamond Therapeutics' current short interest. What is a good short interest ratio for Black Diamond Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. BDTX shares currently have a short interest ratio of 3.0. Learn More on Black Diamond Therapeutics's short interest ratio. Which institutional investors are shorting Black Diamond Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Black Diamond Therapeutics: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Black Diamond Therapeutics' short interest increasing or decreasing? Black Diamond Therapeutics saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 2,000,000 shares, an increase of 13.6% from the previous total of 1,760,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Black Diamond Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the sector of "medical" compare to Black Diamond Therapeutics: Aura Biosciences, Inc. (6.95%), Tenaya Therapeutics, Inc. (5.80%), Solid Biosciences Inc. (3.01%), Ocugen, Inc. (18.61%), Tourmaline Bio, Inc. (20.12%), MeiraGTx Holdings plc (1.76%), Jasper Therapeutics, Inc. (5.21%), TScan Therapeutics, Inc. (1.03%), Caribou Biosciences, Inc. (13.35%), Replimune Group, Inc. (19.05%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Black Diamond Therapeutics stock? Short selling BDTX is an investing strategy that aims to generate trading profit from Black Diamond Therapeutics as its price is falling. BDTX shares are trading down $0.20 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Black Diamond Therapeutics? A short squeeze for Black Diamond Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of BDTX, which in turn drives the price of the stock up even further. How often is Black Diamond Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including BDTX, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: Aura Biosciences Short Squeeze Tenaya Therapeutics Short Squeeze Solid Biosciences Short Squeeze Ocugen Short Squeeze Tourmaline Bio Short Squeeze MeiraGTx Short Squeeze Jasper Therapeutics Short Squeeze TScan Therapeutics Short Squeeze Caribou Biosciences Short Squeeze Replimune Group Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:BDTX) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersDid Intel Just Dethrone Nvidia?Chaikin AnalyticsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsAmerica’s worst nightmare?Porter & CompanyClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsElon’s New Device is About to Shock the WorldInvestorPlaceInvest Now: Starpax's Cancer Breakthrough Achieving What Others Haven't for a CenturyStarpaxTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press